M Laposata

Point-of-care coagulation testing: stepping gently forward.

M. Laposata, M Laposata, 2001, Clinical chemistry.

Covalent binding of arachidonate to G protein alpha subunits of human platelets.

E Belmonte, M. Laposata, L. Brass, 1994, The Journal of biological chemistry.

Utilization and cost analysis of bedside capillary glucose testing in a large teaching hospital: implications for managing point of care testing.

D. Nathan, K. Lewandrowski, M. Laposata, 1994, The American journal of medicine.

Operational Implementation of Prospective Genotyping for Personalized Medicine: The Design of the Vanderbilt PREDICT Project

E. Clayton, J. Schildcrout, J. Peterson, 2012, Clinical pharmacology and therapeutics.

How to work up hypercoagulability.

M Laposata, E M Van Cott, 2000, CAP today.

Expression of rat intestinal fatty acid-binding protein in Escherichia coli. Purification and comparison of ligand binding characteristics with that of Escherichia coli-derived rat liver fatty acid-binding protein.

J B Lowe, J C Sacchettini, J. McQuillan, 1987, The Journal of biological chemistry.

Implementation of capillary blood glucose monitoring in a teaching hospital and determination of program requirements to maintain quality testing.

D. Nathan, K. Lewandrowski, M. Laposata, 1992, The American journal of medicine.

Physician response to implementation of genotype‐tailored antiplatelet therapy

J M Pulley, D M Roden, J. Schildcrout, 2016, Clinical pharmacology and therapeutics.

A membrane lipid imbalance plays a role in the phenotypic expression of cystic fibrosis in cftr(-/-) mice.

S. Freedman, M. Laposata, M Laposata, 1999, Proceedings of the National Academy of Sciences of the United States of America.